Identifying Targets and Drugs for Rheumatoid Arthritis Stratified Therapy Using Mendelian Randomization and a Pretraining Model
Abstract
The prevalence of rheumatoid arthritis (RA) subtypes, including seropositive and seronegative, is influenced by lifestyle factors and exhibits high heterogeneity, resulting in reduced drug efficacy. This study aims to identify cytokines mediating the effects of different lifestyles on RA subtypes and to discover new drugs for personalized treatment. Mendelian randomization revealed that three cytokines (MIP1b, SCGFb, and TRAIL) partially mediated the effects of different lifestyles on RA overall or its subtypes. The pretrained model, i.e., DrugBAN, predicted the probability of 723,000 small molecule drugs binding to these three targets. In molecules with high binding rates, we calculated the structural similarity between known drugs for RA and other drugs to screen for new drugs, followed by molecular docking and molecular dynamics simulations for validation. The results indicate that these targets had promising binding affinity with known drugs and other drugs with high similarity. Our findings may guide therapeutic approaches for heterogeneous RA patients with specific lifestyle habits.
Read the paper
Related studies
- Meta-analysis of genome-wide association for migraine in six population-based European cohorts
- New and sex-specific migraine susceptibility loci identified from a multiethnic genome-wide meta-analysis
- microRNA profiling in atherosclerosis, diabetes, and migraine
- Genome‐Wide‐Associated Variants in Migraine Susceptibility: A Replication Study From North I ndia
- Pharmacoinformatics elucidation of potential drug targets against migraine to target ion channel protein KCNK18
- Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.